This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sandler, A. Articles by Ettinger, D. S. Search for Related Content PubMed PubMed Citation Articles by Sandler, A. Articles by Ettinger, D. S.

Gemcitabine: Single-Agent and Combination Therapy in Non-Small Cell Lung Cancer

^a Indiana University School of Medicine, Hematology/Oncology Division, Indianapolis, Indiana, USA; ^b Johns Hopkins Oncology Center, Baltimore, Maryland, USA

Correspondence: Alan Sandler, M.D., Indiana University School of Medicine, Hematology/Oncology Division, Indiana Cancer Pavilion, 535 Barnhill Drive, Indianapolis, Indiana 46202, USA. Telephone: 317-274-3515; Fax: 317-274-3646; e-mail: asandler{at}iupui.edu

With the advent of several newer agents with single-agent response rates greater than 20% and approximately 30%-40% in combination therapy, non-small cell lung cancer (NSCLC) may now be considered a malignancy that is moderately sensitive to chemotherapy. Examples of these agents include the taxanes, paclitaxel and docetaxel; vinorelbine, a new vinca alkaloid, and the camptothecins, of which CPT-11 is the most actively studied agent. Another new and exciting agent is gemcitabine, a nucleoside analogue structurally related to cytosine arabinoside. Gemcitabine's mechanism of action is activated by deoxycytidine kinase to dFdCMP, dFdCDP and dFdCTP. The latter two compounds, when incorporated into DNA, result in chain termination. Phase I studies using a short infusion schedule given weekly for three weeks followed by one week off established 1,000-1,250 mg/m²/week as the maximum tolerated dose. Single-agent gemcitabine has been extensively studied in patients with chemotherapy-naïve advanced NSCLC with response rates of approximately 20%. Response rates for the combination of gemcitabine plus cisplatin are approximately 28%-54% in phase II trials. Recently, this combination has been studied in randomized phase II and III trials revealing improvements in response rates, time to progression and, in the phase III trial, survival. Current and future studies are evaluating gemcitabine in non-cisplatin combinations (i.e., taxanes).

Key Words. Gemcitabine • Non-small cell lung cancer • Chemotherapy • Metastatic non-small cell lung cancer • Combination chemotherapy

This article has been cited by other articles:

				L. A. Christensen, R. A. Finch, A. J. Booker, and K. M. Vasquez Targeting oncogenes to improve breast cancer chemotherapy. Cancer Res., April 15, 2006; 66(8): 4089 - 4094. [Abstract] [Full Text] [PDF]

				C. Sederholm, G. Hillerdal, K. Lamberg, K. Kolbeck, M. Dufmats, R. Westberg, and S. R. Gawande Phase III Trial of Gemcitabine Plus Carboplatin Versus Single-Agent Gemcitabine in the Treatment of Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: The Swedish Lung Cancer Study Group J. Clin. Oncol., November 20, 2005; 23(33): 8380 - 8388. [Abstract] [Full Text] [PDF]

				B. P. Van Putte, J. M.H. Hendriks, S. Romijn, B. Pauwels, J. B. Vermorken, and P. E.Y. Van Schil Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 125 - 130. [Abstract] [Full Text] [PDF]

				S. Baka, L. Ashcroft, H. Anderson, M. Lind, P. Burt, R. Stout, I. Dowd, D. Smith, P. Lorigan, and N. Thatcher Randomized Phase II Study of Two Gemcitabine Schedules for Patients With Impaired Performance Status (Karnofsky performance status <= 70) and Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., April 1, 2005; 23(10): 2136 - 2144. [Abstract] [Full Text] [PDF]

				R.M. Rudd, N.H. Gower, S.G. Spiro, T.G. Eisen, P.G. Harper, J.A.H. Littler, M. Hatton, P.W.M. Johnson, W.M.C. Martin, E.M. Rankin, et al. Gemcitabine Plus Carboplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer: A Phase III Randomized Study of the London Lung Cancer Group J. Clin. Oncol., January 1, 2005; 23(1): 142 - 153. [Abstract] [Full Text] [PDF]

				M. A. Moufarij, D. R. Phillips, and C. Cullinane Gemcitabine Potentiates Cisplatin Cytotoxicity and Inhibits Repair of Cisplatin-DNA Damage in Ovarian Cancer Cell Lines Mol. Pharmacol., April 1, 2003; 63(4): 862 - 869. [Abstract] [Full Text] [PDF]

				T. S. Lawrence, M. A. Davis, A. Hough, and A. Rehemtulla The Role of Apoptosis in 2',2'-Difluoro-2'-deoxycytidine (Gemcitabine)-mediated Radiosensitization Clin. Cancer Res., February 1, 2001; 7(2): 314 - 319. [Abstract] [Full Text]

				L. L. Nielsen, M. Gurnani, B. Shi, G. Terracina, R. C. Johnson, J. Carroll, J. M. Mathis, and G. Hajian Derivation and Initial Characterization of a Mouse Mammary Tumor Cell Line Carrying the Polyomavirus Middle T Antigen: Utility in the Development of Novel Cancer Therapeutics Cancer Res., December 1, 2000; 60(24): 7066 - 7074. [Abstract] [Full Text]

				L.-Y. Yang, L. Li, H. Jiang, Y. Shen, and W. Plunkett Expression of ERCC1 Antisense RNA Abrogates Gemcitabine-mediated Cytotoxic Synergism with Cisplatin in Human Colon Tumor Cells Defective in Mismatch Repair but Proficient in Nucleotide Excision Repair Clin. Cancer Res., March 1, 2000; 6(3): 773 - 781. [Abstract] [Full Text]

				M. J. Edelman Commentary on "Gemcitabine: Single-Agent and Combination Therapy in Non-Small Cell Lung Cancer" : The Oncologist 1999;4:241-251 Oncologist, June 1, 1999; 4(3): 252 - 255. [Full Text]